Skip to main content
Clinical Trials/ITMCTR2024000084
ITMCTR2024000084
Not yet recruiting
未知

Development and Promotion of Intelligent Diagnostic Equipment for Aplastic Anaemia Based on Traditional Chinese Medicine Digital Four Diagnostics and Deep Learning of Chinese Medicine Evidence

The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional study
Sex
All

Investigators

Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine)

Eligibility Criteria

Inclusion Criteria

  • 1\) Meet the diagnostic criteria for aplastic anaemia;
  • 2\) The patient's age range is 16 to 80 years old;
  • 3\) No standard regimen has been used for treatment after the first diagnosis, or the current regimen has been maintained for more than 3 months;
  • 4\) Sound liver and kidney function (creatinine ?1\.5\*ULN, BUN ?1\.5\*ULN, ALT ?2\*ULN, AST ?2\*ULN, total bilirubin ?1\.5\*ULN);
  • 5\) Able to comply with the study visit schedule and understand and comply with all trial protocol requirements;
  • 6\) Able to understand and voluntarily sign the written informed consent.

Exclusion Criteria

  • 1\) Combination of PNH clones;
  • 2\) Allergy to herbal medicinal tablets;
  • 3\) Severe cardiac disease, including New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled hypertension or hypotension, or severe valvular or endocardial disease resulting in a risk of thromboembolism in the subject;
  • 4\) Clinically significant or uncontrolled persistent inflammatory/autoimmune disease (e.g., rheumatoid arthritis, Crohn's disease, ulcerative colitis, celiac disease, systemic lupus erythematosus, etc.);
  • 5\) Anticipated haematopoietic stem cell transplantation within 3 months.

Outcomes

Primary Outcomes

Not specified

Similar Trials